SBIR-STTR Award

RT-PCR /Elisa Based Method for Leukemia Diagnosis
Award last edited on: 3/18/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$91,078
Award Phase
1
Solicitation Topic Code
394
Principal Investigator
Jian Han

Company Information

Genaco Biomedical Products Inc

2707 Artie Street Building 100 Suite 20
Huntsville, AL 35805
   (256) 425-0051
   info@genaco.com
   www.genaco.com
Location: Single
Congr. District: 05
County: Madison

Phase I

Contract Number: 1R43CA080614-01
Start Date: 2/1/99    Completed: 1/31/00
Phase I year
1999
Phase I Amount
$91,078
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy of childhood. Recurrent chromosome translocations in childhood leukemia are useful cytogenetic markers for diagnosis, prognosis and treatment monitoring. For example, the presence of certain specific translocations, including t(1 ;19), t(9;22) and others defines a group of ALL patients who are at a higher risk of treatment failure. Other abnormalities, including t(12;21), are associated with a group of ALL patients who are at a low risk of treatment failure. Therefore, identification of these abnormalities at the time of diagnosis is essential if appropriate therapy is to be given. We present a novel technology that will allow efficient detection of multiple fusion transcripts at a time. The method could also be used to quantitatively study the expression level of the fusion transcript. Develop such a test kit, therefore, could dramatically improve diagnosis. prognosis and treatment of childhood ALL. PROPOSED COMMERCIAL APPLICATION: Molecular diagnostic kits can be developed based on the proposed research. The kit can provide fast, accurate, sensitive, and quantitative diagnosis of leukemia specific chromosome translocations. Further more, a 96 well ELISA plate formated test could detect as many as 16 common translocations.

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----